logo
  

Takeda : Japan Approves Nuvaxovid COVID-19 Vaccine For Primary And Booster Immunization

Takeda (TAK) said that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for Nuvaxovid Intramuscular Injection or Nuvaxovid, a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older.

Nuvaxovid Intramuscular Injection, containing Matrix-MTM adjuvant, is the first recombinant protein-based COVID-19 vaccine approved for use in Japan.

Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari.

Takeda noted that it will begin distribution of Nuvaxovid doses purchased by the Government of Japan as soon as possible.

Nuvaxovid is stored at a refrigerated temperature of 2 -8? and will be transported using a conventional vaccine supply chain.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT